Author(s): Mindemark M, Larsson A
Abstract Share this page
Abstract OBJECTIVES: To estimate the possible economic effects of a sequential testing strategy with F-calprotectin to minimize colonoscopies. DESIGN AND METHODS: Retrospective study in a third party payer perspective. The costs were calculated from initial F-calprotectin test results of 3639 patients. Two cut-off levels were used: 50 μg/g feces and 100 μg/g feces, respectively. The cost-effectiveness of the testing strategy was estimated through the short-term cost avoidance and reduction in demand for colonoscopies. RESULTS: The estimated demand for colonoscopies was reduced by 50\% with the 50 μg/g cut-off and 67\% with the 100 μg/g cut-off. This corresponded to a cost avoidance of approximately €1.57 million and €2.13 million, respectively. CONCLUSIONS: The use of F-calprotectin as a screening test substantially could reduce the number of invasive measurements necessary in the diagnostic work-up of patients with suspected IBD, as well as the associated costs. Copyright © 2011. Published by Elsevier Inc.
This article was published in Clin Biochem
and referenced in Journal of Clinical & Cellular Immunology